Hopital Tenon

Hopital Tenon is a leading academic medical center conducting comprehensive clinical research across multiple oncology disciplines and complex medical conditions. The institution demonstrates particular strength in precision medicine approaches for advanced malignancies, with extensive experience in evaluating novel immunotherapies, targeted therapies, and antibody-drug conjugates across various cancer types.

• Advanced lung cancer research including NSCLC with molecular alterations (KRAS G12C, RET fusion, EGFR mutations) and small cell lung cancer, evaluating both targeted therapies and immunotherapy combinations
• Comprehensive breast cancer programs spanning HER2-positive and hormone receptor-positive disease, from adjuvant to metastatic settings, including novel drug conjugates and CDK4/6 inhibitor strategies
• Genitourinary oncology focus including prostate cancer (castration-resistant disease with PSMA-targeted radiopharmaceuticals), bladder cancer immunotherapy, and innovative kidney disease management
• Head and neck, gastrointestinal, and rare cancers including locally advanced squamous cell carcinoma, anal cancer, esophageal cancer, and soft tissue sarcomas with multimodal treatment approaches

Beyond oncology, Hopital Tenon maintains robust research programs in infectious diseases (HIV treatment optimization and co-infections), critical care medicine (community-acquired pneumonia, COVID-19, COPD exacerbations, and respiratory failure in immunocompromised patients), and autoimmune disorders (ANCA vasculitis, familial Mediterranean fever, IgA nephropathy, and cutaneous lupus erythematosus). The center's research portfolio reflects expertise in adaptive platform trials, biomarker-driven patient selection, and response-adapted treatment strategies across diverse patient populations.